| Literature DB >> 27033424 |
Shugeng Gao1, Jiagen Li1, Xiaoli Feng2, Susheng Shi2, Jie He1.
Abstract
Primary malignant melanoma of the esophagus (PMME) is an extremely rare disease with poor prognosis. We summarized and analyzed the characteristics of 17 PMME patients (with average age of 57.5 ± 10.3 years) who had received surgical resection in our center. The majority (13/17, 76.5%) of the patients were male. The percentage of patients with smoking and alcohol consumption was 41.2% and 23.5%, respectively. The preoperative diagnosis rate was 35.3%. Lymph node metastasis mainly involved the mid-lower mediastinal and upper abdominal area. Primary tumors that invaded beyond the submucosa layer (T2-T4) had much higher tendency of lymph node metastasis than those restricted to the submucosa layer (T1) (6/8, 75.0% vs. 3/9, 33.3%, p = 0.086). The 1-year and 5-year survival rate of the patients was 51% and 10%, respectively, with median survival time being 18.1 months. Survival analysis showed that TNM stage was a predictor for PMME prognosis (median survival time of 47.3 months vs. 8.0 months for stage I/II vs. stage III, respectively, p = 0.018), and multivariable Cox regression analysis revealed the independence of its prognostic value [HR (95% CI): 5.678 (1.125-28.658), p = 0.035].Entities:
Mesh:
Year: 2016 PMID: 27033424 PMCID: PMC4817120 DOI: 10.1038/srep23804
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographic and clinical characteristics of the PMME patients.
| Case No. | Age | Gender | Tobacco use | Alcohol use | Family history | Chief complaint | Months between onset and diagnosis | Preoperative diagnosis | Preoperative treatment | Comorbidity | Vital status | Survival time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 73 | male | no | no | no | dysphagia | 3.0 | ESCC | no | no | Dead | 7.1 |
| 2 | 68 | male | yes | no | yes | dysphagia | 12.0 | ESCC | no | no | Alive | 26.1 |
| 3 | 71 | male | no | no | yes | dysphagia | 2.0 | MME | no | no | Alive | 8.1 |
| 4 | 54 | male | yes | yes | no | dysphagia | 2.0 | MME | no | no | Alive | 8.4 |
| 5 | 63 | male | yes | no | no | dysphagia | 2.0 | MME | no | no | Dead | 25.1 |
| 6 | 67 | female | no | no | no | dysphagia | 2.0 | MME | no | no | Dead | 47.3 |
| 7 | 43 | female | no | no | no | dysphagia | 0.7 | MME | no | no | Dead | 4.3 |
| 8 | 55 | male | no | no | no | dysphagia | 1.0 | Unspecified | no | no | Dead | 1.9 |
| 9 | 60 | male | no | no | no | dysphagia | 1.7 | Unspecified | no | no | Dead | 18.6 |
| 10 | 70 | male | yes | yes | no | dysphagia | 6.0 | Unspecified | no | HTN + DM | Dead | 10.4 |
| 11 | 50 | male | yes | no | no | haematemesis | 1.3 | EAC | no | no | Dead | 24.3 |
| 12 | 57 | male | no | no | no | dysphagia | 4.0 | Unspecified | no | no | Dead | 7.0 |
| 13 | 43 | male | yes | yes | no | dysphagia | 4.0 | ESCC | no | no | Dead | 8.0 |
| 14 | 56 | male | no | no | no | dysphagia | 3.0 | MME | no | no | Dead | 54.0 |
| 15 | 41 | female | no | no | no | belly ache | 1.0 | Unspecified | no | no | Dead | 5.0 |
| 16 | 46 | female | no | no | no | dysphagia | 3.0 | Unspecified | Radiotherapy | CHD | Dead | 204 |
| 17 | 60 | male | yes | yes | no | dysphagia | 2.0 | ESCC | no | no | Dead | 8.0 |
aFamily history of UGI(upper gastro-intestinal tract) cancer.
bmonths. ESCC, esophageal squamous cell carcinoma. MME, malignant melanoma of esophagus. EAC, esophageal adenocarcinoma. HTN, hypertension. DM, diabetes mellitus. CHD, coronary heart disease.
Figure 1Barium swallow exam revealed an irregular filling defect on the lower third of the esophagus, causing mucosa destruction (a). Upper gastrointestinal endoscopy highlighted an irregular mass in the esophageal lumen with rough and pigmented surface (b) which was easily bleeding (c).
Figure 2Immunohistochemical staining with HMB45 (human melanoma black 45) antibody revealed positive tumor cells in the esophageal mucosa of preoperative endoscopic biopsy (a, ×200). H&E staining identified malignant melanoma cells in the lamina propria of the esophagus (b, ×200)
Surgery and pathological features of the PMME patients.
| Case No. | Surgery time (min) | Blood loss (ml) | Complication | Tumor size (cm) | Location | Invasion depth | T stage | Dissected LN | LNM | N stage | TNM stage | LNM area |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 210 | 600 | Arrhythmia | 8.0 | Mid | Fibrous membrane | 3 | 20 | 2 | 1 | III | Upper abdominal |
| 2 | 190 | 200 | Arrhythmia | 7.5 | Mid | Fibrous membrane | 3 | 19 | 0 | 0 | II | – |
| 3 | 220 | 100 | Arrhythmia | 7.0 | Mid | Submucosa | 1b | 43 | 9 | 3 | III | Mid-lower mediastinal |
| 4 | 170 | 100 | No | 4.2 | Lower | Submucosa | 1b | 19 | 0 | 0 | I | – |
| 5 | 200 | 200 | Arrhythmia | 4.0 | Mid | Submucosa | 1b | 22 | 1 | 1 | II | Upper abdominal |
| 6 | 200 | 200 | Arrhythmia | 2.7 | Upper | Submucosa | 1b | 14 | 0 | 0 | I | – |
| 7 | 200 | 200 | No | 4.5 | Mid | Submucosa | 1b | 20 | 0 | 0 | I | – |
| 8 | 170 | 300 | Arrhythmia + Leakage + BPF | 5.0 | Mid | Submucosa | 1b | 21 | 0 | 0 | I | – |
| 9 | 210 | 300 | No | 6.0 | Lower | Beyond serosa | 4a | 23 | 1 | 1 | III | Upper abdominal |
| 10 | 170 | 200 | No | 6.5 | Lower | Deep muscular | 2 | 19 | 11 | 3 | III | Mid-lower mediastinal |
| 11 | 130 | 400 | No | 2.5 | Lower | Beyond serosa | 4a | 11 | 0 | 0 | III | – |
| 12 | 210 | 600 | No | 7.0 | Lower | Beyond serosa | 4a | 2 | 2 | 1 | III | Upper abdominal |
| 13 | 270 | 400 | No | 10.0 | Mid | Submucosa | 1b | 16 | 0 | 0 | I | – |
| 14 | 210 | 500 | No | 5.0 | Lower | Submucosa | 1b | 9 | 1 | 1 | II | Upper abdominal |
| 15 | 120 | 400 | No | 3.0 | Lower | Beyond serosa | 4a | 8 | 7 | 3 | III | Upper abdominal |
| 16 | 180 | 300 | No | 10.0 | Lower | Mucosa | 1a | 3 | 0 | 0 | I | – |
| 17 | 200 | 300 | No | 7.0 | Lower | Fibrous membrane | 3 | 23 | 1 | 1 | III | – |
BPF, bronchopleural fistula. LN, lymph node. LNM, lymph node metastasis. TNM, tumor, lymph node, metastasis.
Figure 3TNM stage was associated with overall survival of PMME patients. Kaplan-Meier survival curves of stage III vs. stage I~II patients.
The p value was calculated by log-rank test.
Univariate and multivariate Cox regression analyses of the clinical and pathological factors with survival of PMME patients (n = 16).
| Univariate analysis | Multivariate analysis | Hazard ratio (95% CI) | |||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | |||||
| Age | >60 vs. ≤60 | 0.717 (0.208–2.479) | 0.5995 | − | − |
| Gender | Female vs. Male | 0.783 (0.196–3.126) | 0.7288 | − | − |
| Tobacco use | Yes vs. No | 1.026 (0.294–3.574) | 0.9684 | − | − |
| Alcohol use | Yes vs. No | 2.051 (0.448–9.397) | 0.3550 | − | − |
| Tumor location | Lower vs. Upper + Middle | 0.927 (0.280–3.070) | 0.9013 | − | − |
| T | T2 + T3 + T4 vs. T1 | 3.262 (0.818–13.004) | 0.0938 | − | − |
| N | N1 + N2 + N3 vs. N0 | 2.211 (0.655–7.469) | 0.2013 | − | − |
| TNM | III vs. I + II | 5.678 (1.125–28.658) | 0.0355 | 5.678 (1.125–28.658) | 0·0355 |
| Complication | Yes vs. No | 0.577 (0.150–2.216) | 0.4231 | − | − |
CI, confidential interval.
Figure 4Association of lymph node metastasis and survival of PMME patients.
Kaplan-Meier curves of node metastasis involvement status. LNM: lymph node metastasis.